Randomised clinical trial: the efficacy and safety of oltipraz, a liver X receptor alpha‐inhibitory dithiolethione in patients with non‐alcoholic fatty liver disease (English)
- New search for: Kim, W.
- New search for: Kim, B. G.
- New search for: Lee, J. S.
- New search for: Lee, C. K.
- New search for: Yeon, J. E.
- New search for: Chang, M. S.
- New search for: Kim, J. H.
- New search for: Kim, H.
- New search for: Yi, S.
- New search for: Lee, J.
- New search for: Cho, J.‐Y.
- New search for: Kim, S. G.
- New search for: Lee, J.‐H.
- New search for: Kim, Y. J.
- New search for: Kim, W.
- New search for: Kim, B. G.
- New search for: Lee, J. S.
- New search for: Lee, C. K.
- New search for: Yeon, J. E.
- New search for: Chang, M. S.
- New search for: Kim, J. H.
- New search for: Kim, H.
- New search for: Yi, S.
- New search for: Lee, J.
- New search for: Cho, J.‐Y.
- New search for: Kim, S. G.
- New search for: Lee, J.‐H.
- New search for: Kim, Y. J.
In:
Alimentary Pharmacology & Therapeutics
;
45
, 8
;
1073-1083
;
2017
- Article (Journal) / Electronic Resource
-
Title:Randomised clinical trial: the efficacy and safety of oltipraz, a liver X receptor alpha‐inhibitory dithiolethione in patients with non‐alcoholic fatty liver disease
-
Contributors:Kim, W. ( author ) / Kim, B. G. ( author ) / Lee, J. S. ( author ) / Lee, C. K. ( author ) / Yeon, J. E. ( author ) / Chang, M. S. ( author ) / Kim, J. H. ( author ) / Kim, H. ( author ) / Yi, S. ( author ) / Lee, J. ( author )
-
Published in:Alimentary Pharmacology & Therapeutics ; 45, 8 ; 1073-1083
-
Publisher:
-
Publication date:2017-04-01
-
Size:11 pages
-
ISSN:
-
DOI:
-
Type of media:Article (Journal)
-
Type of material:Electronic Resource
-
Language:English
-
Source:
Table of contents – Volume 45, Issue 8
The tables of contents are generated automatically and are based on the data records of the individual contributions available in the index of the TIB portal. The display of the Tables of Contents may therefore be incomplete.
- 1011
-
Systematic review with meta‐analysis: the impact of Clostridium difficile infection on the short‐ and long‐term risks of colectomy in inflammatory bowel diseaseLaw, C. C. Y. / Tariq, R. / Khanna, S. / Murthy, S. / McCurdy, J. D. et al. | 2017
- 1021
-
Systematic review with meta‐analysis: placebo rates in induction and maintenance trials of Crohn's diseaseJairath, V. / Zou, G. / Parker, C. E. / MacDonald, J. K. / Mosli, M. H. / AlAmeel, T. / Al Beshir, M. / AlMadi, M. / Al‐Taweel, T. / Atkinson, N. S. S. et al. | 2017
- 1043
-
Systematic review with meta‐analysis: the efficacy and safety of CT‐P13, a biosimilar of anti‐tumour necrosis factor‐α agent (infliximab), in inflammatory bowel diseasesKomaki, Y. / Yamada, A. / Komaki, F. / Micic, D. / Ido, A. / Sakuraba, A. et al. | 2017
- 1058
-
Review article: moving towards common therapeutic goals in Crohn's disease and rheumatoid arthritisAllen, P. B. / Olivera, P. / Emery, P. / Moulin, D. / Jouzeau, J.‐Y. / Netter, P. / Danese, S. / Feagan, B. / Sandborn, W. J. / Peyrin‐Biroulet, L. et al. | 2017
- 1073
-
Randomised clinical trial: the efficacy and safety of oltipraz, a liver X receptor alpha‐inhibitory dithiolethione in patients with non‐alcoholic fatty liver diseaseKim, W. / Kim, B. G. / Lee, J. S. / Lee, C. K. / Yeon, J. E. / Chang, M. S. / Kim, J. H. / Kim, H. / Yi, S. / Lee, J. et al. | 2017
- 1084
-
Factors associated with villus atrophy in symptomatic coeliac disease patients on a gluten‐free dietMahadev, S. / Murray, J. A. / Wu, T.‐T. / Chandan, V. S. / Torbenson, M. S. / Kelly, C. P. / Maki, M. / Green, P. H. R. / Adelman, D. / Lebwohl, B. et al. | 2017
- 1094
-
Predictors of response to a low‐FODMAP diet in patients with functional gastrointestinal disorders and lactose or fructose intoleranceWilder‐Smith, C. H. / Olesen, S. S. / Materna, A. / Drewes, A. M. et al. | 2017
- 1107
-
Inflammatory bowel diseases in Faroese‐born Danish residents and their offspring: further evidence of the dominant role of environmental factors in IBD developmentHammer, T. / Lophaven, S. N. / Nielsen, K. R. / von Euler‐Chelpin, M. / Weihe, P. / Munkholm, P. / Burisch, J. / Lynge, E. et al. | 2017
- 1115
-
Epidemiology of inflammatory bowel disease among participants of the Millennium Cohort: incidence, deployment‐related risk factors, and antecedent episodes of infectious gastroenteritisPorter, C. K. / Welsh, M. / Riddle, M. S. / Nieh, C. / Boyko, E. J. / Gackstetter, G. / Hooper, T. I. et al. | 2017
- 1128
-
Suppression of anti‐drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel diseaseStrik, A. S. / van den Brink, G. R. / Ponsioen, C. / Mathot, R. / Löwenberg, M. / D'Haens, G. R. et al. | 2017
- 1135
-
Intra‐patient variability in adalimumab drug levels within and between cycles in Crohn's diseaseWard, M. G. / Thwaites, P. A. / Beswick, L. / Hogg, J. / Rosella, G. / Van Langenberg, D. / Reynolds, J. / Gibson, P. R. / Sparrow, M. P. et al. | 2017
- 1146
-
On‐target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi‐centre, prospective studyHowell, J. / Pinato, D. J. / Ramaswami, R. / Bettinger, D. / Arizumi, T. / Ferrari, C. / Yen, C. / Gibbin, A. / Burlone, M. E. / Guaschino, G. et al. | 2017
- 1156
-
Hepatitis B reactivation in patients with chronic hepatitis C undergoing anti‐viral therapy with an interferon‐free regimenLondoño, M.‐C. / Lens, S. / Mariño, Z. / Bonacci, M. / Ariza, X. / Broquetas, T. / Pla, A. / Bartres, C. / Adriani, M. V. / Rodríguez‐Tajes, S. et al. | 2017
- 1162
-
Editorial: smoking status and 5‐year survival in patients with colorectal cancerHo, N. / Lieberman, D. et al. | 2017
- 1163
-
Editorial: scoring systems in primary biliary cholangitis – time to make a moveMells, G. F. / Jones, D. E. et al. | 2017
- 1164
-
Editorial: scoring systems in primary biliary cholangitis – time to make a move. Authors’ replyYang, F. / Yang, Y. / Tang, R. / Gershwin, M. E. / Ma, X. et al. | 2017
- 1165
-
Editorial: elemental diets for eosinophilic oesophagitisKatzka, D. A. et al. | 2017
- 1167
-
Editorial: co‐existing immune‐mediated disease in inflammatory bowel diseases – a new disease severity indicator?Vegh, Z. / Bessissow, T. / Afif, W. / Lakatos, P. L. et al. | 2017
- 1168
-
Editorial: co‐existing immune‐mediated disease in inflammatory bowel diseases – a new disease severity indicator? Author's replyAnanthakrishnan, A. N. et al. | 2017
- 1169
-
Letter: dose optimising infliximab in acute severe ulcerative colitisChoy, M. C. / De Cruz, P. et al. | 2017
- 1170
-
Letter: dose optimising infliximab in acute severe ulcerative colitis – authors' replyJairath, V. / Casteele, N. V. / Hindryckx, P. et al. | 2017
- 1171
-
Letter: sustained virological response and liver healingRossotti, R. / Garcia‐Fraile Fraile, L. J. / Baiguera, C. / Puoti, M. et al. | 2017
- 1173
-
Letter: sustained virological response and liver healing – authors' replyMandorfer, M. / Schwabl, P. / Peck‐Radosavljevic, M. / Reiberger, T. / the Vienna HIV & Liver Study Group and the Vienna Hepatic Hemodynamic Lab et al. | 2017
- 1175
-
Letter: NICE referral criteria for lower gastrointestinal alarm features – not ideal but not poor eitherMin, L. / Zhao, Y. / Xing, J. / Zhang, S. et al. | 2017
- 1176
-
Letter: NICE referral criteria for lower gastrointestinal alarm features – not ideal but not poor either. Authors' replySimpkins, S. J. / Pintos‐Sanchez, M. I. / Moayyedi, P. / Bercik, P. / Morgan, D. G. / Bolino, C. / Ford, A. C. et al. | 2017
- 1177
-
Letter: how to define remission in ulcerative colitis – histological remission should be consideredKilincalp, S. / Ustun, Y. / Şimşek, Z. et al. | 2017
- 1177
-
Letter: how to define remission in ulcerative colitis – histological remission should be considered. Authors' replyAngelison, L / Marsal, J. / Hertervig, E. et al. | 2017